import { useState, useRef, useEffect } from "react"; const COMPANIES = [ { id:1, name:"Lonza Group", type:"CDMO · Biologics & Small Molecule", location:"Basel, Switzerland · Global", logo:"LZ", color:"#1a3a2a", score:97, alerts:0, lastUpdate:"1 hour ago", capabilities:["API & HPAPI Manufacture","mAbs & Recombinant Proteins","Vaccines & Plasmid DNA","Cell & Gene Therapy"], stage:"Pre-clinical to Commercial" }, { id:2, name:"Menarini Biotech", type:"CDMO · Biologics", location:"Pomezia, Rome, Italy", logo:"MB", color:"#2d5a3d", score:91, alerts:0, lastUpdate:"3 hours ago", capabilities:["mAbs & Bispecifics","ADCs & Bioconjugation","CHO Cell Line Development","Fusion Proteins & HPAPIs"], stage:"Pre-clinical to Phase III" }, { id:3, name:"Fisiopharma", type:"CDMO · Injectable Manufacturing", location:"Palomonte, Italy · Hefei, China", logo:"FP", color:"#8B6914", score:88, alerts:1, lastUpdate:"6 hours ago", capabilities:["Sterile Injectables","Suspensions & Nanoemulsions","Aseptic & Terminal Sterilisation","Formulation Development"], stage:"Development to Commercial" }, ]; const SEARCH_RESPONSES = [ { triggers: ["cytotoxic","high potency api","hpapi formulation","formulation capacity","manufacture cytotoxic","high potency"], response: `This is a highly specialised requirement — cytotoxic HPAPI manufacture combined with formulation capability under one roof in Europe. Let me refine the match with one question: What is the containment level required for your API — OEB4 or OEB5? And are you looking for integrated manufacture and formulation from the same site, or would a two-site European supply chain be acceptable? Based on your query, Lonza Group is the strongest match in this network. Their European facilities — principally Visp, Switzerland — include dedicated HPAPI synthesis suites rated to OEB5 containment, covering pre-clinical through commercial scale. Importantly, Lonza also offers downstream formulation and fill-finish capabilities, meaning cytotoxic API manufacture and formulation can be managed within a single CDMO relationship, significantly reducing supply chain complexity and regulatory burden. For programmes where the cytotoxic API is destined for an ADC payload, Menarini Biotech in Pomezia, Italy is also highly relevant — their bioconjugation platform is specifically designed to handle cytotoxic payloads and link them to antibodies under appropriate containment, complementing upstream HPAPI synthesis from Lonza. Both companies are EU GMP certified, removing any additional regulatory bridging requirements for European market supply. Shall I outline what a dual-CDMO strategy across Lonza and Menarini Biotech might look like for an ADC programme?` }, { triggers: ["adc","antibody-drug","antibody drug","bioconjug"], response: `Great question — ADC development is a highly specialised capability. Before I recommend, a couple of quick questions to sharpen the match: 1. What is the nature of your payload — small molecule cytotoxin, radioisotope, or other? 2. Do you need cell line development included, or do you already have an established antibody? Based on your pre-clinical to Phase III requirement, Menarini Biotech (Pomezia, Rome) is your strongest match in this network. They are a fully integrated biologics CDMO with dedicated ADC and bioconjugation capabilities, CHO cell line development, and a BSL-2 capable single-use facility — all under AIFA/EU GMP certification. They are specifically positioned to partner with emerging biotech from pre-clinical through late-phase clinical manufacture. Lonza Group is also worth noting for their HPAPI synthesis capabilities if your ADC payload requires high-potency handling at commercial scale — they can complement a Menarini engagement or take over at commercialisation. Shall I provide a more detailed comparison of both options?` }, { triggers: ["injectable","sterile","suspension","vial","ampoule","fill finish"], response: `For sterile injectable manufacturing, the network has a strong match. A few quick questions: 1. What is the dosage form — solution, suspension, lyophilised powder, or nanoemulsion? 2. Which regulatory markets are you targeting (EU, US, emerging markets)? Fisiopharma (Palomonte, Italy / Hefei, China) is your primary match. They are a specialist injectable CDMO with over 35 years of experience manufacturing sterile solutions, suspensions, nanoemulsions, and powders in vials and ampoules — via both aseptic filling and terminal sterilisation. Critically, they hold approvals from EMA/AIFA, US-FDA, ANVISA, NMPA, and Saudi-FDA, making them an excellent partner if you need multi-market regulatory coverage. They also offer full formulation and analytical development, technology transfer, and regulatory dossier preparation — a comprehensive CDMO package. Would you like me to outline what an onboarding process with Fisiopharma might look like?` }, { triggers: ["mab","monoclonal","bispecific","antibody","protein","biologic","recombinant"], response: `For monoclonal antibody or biologic development, the network offers two strong options depending on your scale and phase. Before recommending, two quick questions: 1. What development phase are you currently at, and what is your target indication? 2. Are you working with an established cell line, or do you need cell line development included? Menarini Biotech is well-suited for mAb, bispecific, and fusion protein development from pre-clinical through Phase III. Their single-use CHO platform, process and analytical development capabilities, and AIFA/EU GMP certification make them an agile, responsive partner — particularly for emerging biotech companies. Lonza Group is the natural choice for late-phase and commercial-scale biologics manufacture. Their breadth of bioprocessing platforms (CHO, microbial, conjugation chemistry) and global manufacturing network provide the scale and regulatory track record to support BLA/MAA submissions. A common strategy is to partner with Menarini for early phase development and plan a technology transfer to Lonza for commercial scale. Would that model be of interest?` }, { triggers: ["api","small molecule","synthesis","oncology"], response: `For API or HPAPI synthesis, the network has a clear recommendation. Lonza Group is your strongest match. They are one of the world's leading CDMOs for both standard API manufacture and High Potency API synthesis, with dedicated containment facilities rated to OEB5. Their process chemistry platforms span custom synthesis, fermentation, and conjugation chemistry — covering pre-clinical gram quantities through to multi-tonne commercial supply. For oncology programmes requiring cytotoxic payloads combined with biologics (i.e. ADC programmes), Lonza's HPAPI capability pairs naturally with Menarini Biotech's ADC bioconjugation platform — a combination that several emerging biotech companies have used to keep their supply chain within a trusted European CDMO network. What phase is your programme currently at, and are you working with a novel synthetic route or an established process?` }, { triggers: ["vaccine","plasmid","dna","gene therapy","viral vector","rna","mrna"], response: `For vaccine, plasmid DNA, or gene therapy manufacturing, Lonza Group is the clear recommendation from this network. They have dedicated capability in: - Plasmid DNA manufacture for gene therapy and DNA vaccine applications - Viral vectors (AAV, lentiviral) for cell and gene therapy - mRNA and nucleic acid platforms - Mammalian and microbial fermentation at clinical and commercial scale Lonza's Visp and Portsmouth sites are specifically equipped for advanced therapy medicinal products (ATMPs) and have supported multiple IND/CTA and BLA/MAA filings in this space. A quick question: are you working on an in vivo gene therapy, ex vivo cell therapy, or a nucleic acid vaccine platform? This will help me refine whether you need plasmid DNA supply only, or a more integrated ATMP manufacturing partnership.` }, ]; const DEFAULT_RESPONSE = `Thank you for your enquiry. To ensure I match you with the right partner from our vetted network, could you help me with two quick questions: 1. What type of molecule or therapeutic modality are you working with (small molecule, biologic, injectable, gene therapy)? 2. What development phase are you currently at, and which regulatory markets are you targeting? Our network includes specialist CDMOs covering biologics manufacture, ADC development, injectable manufacturing, API synthesis, and gene therapy — each with distinct strengths. With a little more detail I can give you a precise, reasoned recommendation.`; const PROFILE_DATA = { "1-overview": `Lonza Group holds a Partnership Readiness Score of 97/100 — the highest in this network — reflecting their unmatched breadth of capability, global manufacturing footprint, and regulatory track record. As a CDMO partner, Lonza's key differentiators are their ability to support a programme from first-in-human synthesis through to multi-tonne commercial supply without requiring technology transfer to a third party. Their bioprocessing platforms — CHO mammalian cell culture, microbial fermentation, HPAPI containment, and plasmid DNA manufacture — cover the widest range of modalities in the industry. Lonza is best suited to: emerging biotech seeking a single strategic CDMO partner for the full development lifecycle; large pharma requiring surge capacity or specialist containment for HPAPI programmes; and cell & gene therapy developers needing ATMP-grade plasmid DNA or viral vector supply.`, "1-regulatory": `Lonza operates GMP-certified manufacturing sites across Basel and Visp (Switzerland), Portsmouth NH (USA), Guangzhou (China), and Singapore — all operating under current GMP. Recent regulatory activity: Lonza's Portsmouth, NH facility received a Voluntary Action Indicated (VAI) outcome following a US-FDA inspection in Q4 2025 (EIR Ref: 3015283881), with no critical observations noted. The Visp biologics site successfully completed an EMA joint inspection in January 2026 with zero critical findings. Lonza holds active Drug Master Files (DMFs) with the FDA for over 200 API processes, supporting client IND, NDA, and BLA submissions. An EMA inspection of the Guangzhou API facility is scheduled for Q3 2026 in preparation for expanding EU market supply.`, "1-financials": `Lonza Group (SIX: LONN) reported full-year 2025 revenues of approximately CHF 6.2 billion, with the Biologics and Small Molecules divisions contributing the majority of CDMO revenue. The company employs approximately 17,500 people globally. In 2025, Lonza committed CHF 800 million in capital investment towards expanding its Visp biologics campus and adding new HPAPI containment suites at Portsmouth. A new cell & gene therapy manufacturing facility in Geleen, Netherlands is scheduled to come online in Q4 2026. Partnership pipeline: Lonza's commercial appetite for new CDMO partnerships is active, with a stated strategic focus on cell & gene therapy, ADC payloads, and biologics for emerging market clients.`, "1-news": `📰 14 Feb 2026 — Lonza announces expansion of ADC payload manufacturing capacity at Portsmouth Lonza confirmed a USD 120M investment to add three new HPAPI suites at its Portsmouth, NH site, increasing OEB5-rated capacity by 40% to meet growing ADC programme demand. 📰 28 Jan 2026 — Lonza presents cell & gene therapy plasmid DNA platform at Advanced Therapies Week, London Lonza's Gene Therapy team presented process intensification data for their plasmid DNA platform, demonstrating 3x yield improvements versus 2023 baseline. 📰 09 Jan 2026 — Lonza signs long-term biologics manufacturing partnership with US-based oncology biotech A multi-year CDMO agreement was confirmed for manufacture of a bispecific antibody programme from Phase II through commercial supply, valued at up to USD 280M over the term.`, "2-overview": `Menarini Biotech holds a Partnership Readiness Score of 91/100, reflecting their fully integrated biologics capability, strong GMP track record, and particular strength as a partner for emerging biotech companies that need an agile, responsive CDMO. As a CDMO partner, Menarini Biotech's key differentiators are their expertise in complex biologics — particularly ADCs, bispecific antibodies, and bioconjugation — combined with a modern single-use facility and BSL-2 capability. Their integrated offering spans CHO cell line development, upstream and downstream processing, aseptic fill-finish, and analytical development under one roof in Pomezia, Italy. Menarini Biotech is best suited to: emerging biotech companies seeking a European biologics CDMO with genuine technical expertise; ADC and bispecific programmes requiring specialised bioconjugation chemistry; and companies that need a pre-clinical to Phase III partner without the scale overhead of larger CDMOs.`, "2-regulatory": `Menarini Biotech's Pomezia facility operates under AIFA (Italian Medicines Agency) GMP authorisation and EU GMP certification, valid through December 2026. The site is BSL-2 rated and operates dedicated single-use manufacturing suites under full environmental monitoring. The facility received a routine AIFA GMP inspection in September 2025 (Ref: AIFA/GMP/2025/IT-0447) with no critical observations. A minor observation regarding temperature mapping documentation was closed within 30 days with an accepted CAPA. Menarini Biotech routinely supports client CTA and IND submissions, with an in-house regulatory affairs team experienced in EMA and EU member state submissions. They are actively preparing for an FDA pre-approval inspection in connection with a partnered Phase III programme expected in H2 2026.`, "2-financials": `Menarini Biotech operates as part of the Menarini Group — one of Italy's largest privately held pharmaceutical companies, with group revenues exceeding EUR 4.2 billion in 2024 and operations in over 140 countries. The Pomezia biologics site employs approximately 160 specialist staff and has undergone significant capital investment since 2019, including the installation of single-use bioreactor trains (50L–2,000L) and a dedicated ADC/bioconjugation suite. Partnership pipeline: Menarini Biotech is actively seeking 2–3 new CDMO partnerships in 2026, with a preference for programmes that can grow through Phase III and into commercial supply.`, "2-news": `📰 18 Feb 2026 — Menarini Biotech presents ADC bioconjugation platform data at PEGS Europe, Lisbon The process development team presented conjugation efficiency and DAR homogeneity data from their site-specific ADC platform, demonstrating industry-leading payload-to-antibody ratios across three clinical-stage molecules. 📰 03 Feb 2026 — Menarini Biotech signs Phase I/II manufacturing agreement with UK oncology biotech A new CDMO partnership was confirmed for manufacture of a CD3 bispecific antibody for a solid tumour indication, covering cell line development through Phase II clinical supply. 📰 15 Jan 2026 — Menarini Group confirms EUR 45M investment in Pomezia biologics site expansion A new 500m² analytical development laboratory and additional single-use upstream manufacturing capacity, expected to be operational by Q1 2027.`, "3-overview": `Fisiopharma holds a Partnership Readiness Score of 88/100, reflecting their strong multi-authority regulatory approvals, long-established injectable expertise, and broad geographic reach through their Italian and Chinese manufacturing sites. As a CDMO partner, Fisiopharma's key differentiator is their breadth of injectable dosage forms combined with approvals across five major regulatory markets simultaneously. Their capability spans sterile solutions, suspensions, nanoemulsions, and lyophilised powders, with both aseptic filling and terminal sterilisation lines available. Fisiopharma is best suited to: companies requiring sterile injectable supply for EU and emerging market regulatory submissions; programmes involving complex dosage forms such as nanoemulsions or suspensions; and clinical stage companies needing a full-service CDMO covering formulation development through to commercial serialised supply.`, "3-regulatory": `Fisiopharma's Palomonte site holds simultaneous GMP certification from EMA/AIFA, US-FDA, ANVISA (Brazil), NMPA (China), and Saudi-FDA — one of the broadest multi-authority approval profiles in the European injectable CDMO sector. The site completed a US-FDA inspection in October 2025 (EIR Ref: 3008941762) with a VAI outcome and one minor observation relating to aseptic line clearance documentation, addressed via a submitted CAPA in November 2025. An ANVISA re-certification inspection is scheduled for May 2026. Fisiopharma's in-house regulatory team prepares full eCTD dossier sections for client submissions across all approved markets, including Module 3 CMC documentation.`, "3-financials": `Fisiopharma is a wholly owned subsidiary of Yifan Pharmaceuticals Ltd, a Chinese pharmaceutical group with 20 production facilities, approximately 5,000 employees globally, and consolidated revenues exceeding CNY 3.5 billion (approx. EUR 450M). The Palomonte site employs approximately 140 people. A laboratory expansion completed in 2021 added new analytical and formulation development capacity. A further site expansion currently underway — expected completion Q3 2026 — will add pre-filled syringe filling capability to complement existing vial and ampoule lines. Fisiopharma is actively seeking new CDMO partnerships, particularly for programmes requiring multi-market regulatory coverage.`, "3-news": `📰 21 Feb 2026 — Fisiopharma completes installation of pre-filled syringe filling line at Palomonte The new automated syringe filling and inspection line passed IQ/OQ validation, with PQ runs scheduled for March 2026, expanding dosage form capabilities to include PFS for EU and US markets. 📰 05 Feb 2026 — Fisiopharma exhibits at CDMO Live Europe, Amsterdam Fisiopharma's Business Development team presented their multi-authority approval portfolio to over 80 potential partners, generating 12 qualified leads for new development programmes. 📰 20 Jan 2026 — Fisiopharma confirms new CDMO agreement for corticosteroid suspension programme A new manufacturing partnership was signed with a European specialty pharma company for development and commercial supply of a proprietary corticosteroid suspension.`, }; function getResponse(query) { const q = query.toLowerCase(); for (const item of SEARCH_RESPONSES) { if (item.triggers.some(t => q.includes(t))) return item.response; } return DEFAULT_RESPONSE; } function Spinner() { return {[0,1,2].map(i=>)} ; } function ScoreRing({score, size=48}) { const color = score>=90?"#2d7a4f":score>=80?"#c9a84c":"#c0392b"; return (
52?16:12,fontWeight:800,color}}>{score}
); } function CompanyCard({company, selected, onClick}) { return (
onClick(company)} style={{background:selected?"#1a3a2a":"#fff",border:`2px solid ${selected?"#c9a84c":"#d8e2da"}`,borderRadius:12,padding:16,cursor:"pointer",marginBottom:12,transition:"all 0.15s"}}>
{company.logo}
{company.name}
{company.type}
📍 {company.location}
{company.capabilities.slice(0,2).map(cap=>( {cap} ))}
Updated {company.lastUpdate} {company.alerts>0&&{company.alerts} alert}
); } export default function App() { const [tab,setTab]=useState("search"); const [query,setQuery]=useState(""); const [chat,setChat]=useState([]); const [busy,setBusy]=useState(false); const [selCo,setSelCo]=useState(COMPANIES[0]); const [profTab,setProfTab]=useState("overview"); const [profLoading,setProfLoading]=useState(false); const [profVisible,setProfVisible]=useState(true); const bottomRef=useRef(null); useEffect(()=>{bottomRef.current?.scrollIntoView({behavior:"smooth"});},[chat]); useEffect(()=>{ setProfVisible(false); setProfLoading(true); const t=setTimeout(()=>{setProfLoading(false);setProfVisible(true);},900); return ()=>clearTimeout(t); },[selCo,profTab]); function handleSearch() { const txt=query.trim(); if(!txt||busy) return; setQuery(""); setChat(p=>[...p,{role:"user",content:txt}]); setBusy(true); setTimeout(()=>{ setChat(p=>[...p,{role:"assistant",content:getResponse(txt)}]); setBusy(false); },1400); } const PTABS=["overview","regulatory","financials","news"]; const profKey=`${selCo?.id}-${profTab}`; return (
{/* ── BANNER ── */}
🌿
The Partnership Tree
A searchable curated network and management platform for the Life Science sector
{/* ── TAB BUTTONS ── */}
{[["search","🔍 Partner Search"],["profiles","📊 Living Profiles — Results"]].map(([k,l])=>( ))}
{/* ══ SEARCH TAB ══ */} {tab==="search"&&(
Find Your Perfect Partner
Describe your need in plain language. Our AI powered search finds matches for you from our curated network of thousands of companies.
{/* Chat messages */}
{chat.length===0&&(
🌿
Tell us what you need below
Describe your partnership requirements and our AI consultant will match you with vetted companies from the network.
Sample Searches
{[ "Can you suggest companies with the capacity to manufacture cytotoxic High Potency APIs and also with formulation capacity within Europe", "I need a CDMO for ADC development from pre-clinical to Phase III", "We need sterile injectable manufacturing for a complex suspension", "Looking for mAb manufacture from cell line development to Phase III", ].map(s=>( ))}
)} {chat.map((msg,i)=>(
{msg.role==="assistant"&&
AI Partnership Consultant
} {msg.content}
))} {busy&&(
)}
{/* Input bar */}
setQuery(e.target.value)} onKeyDown={e=>e.key==="Enter"&&handleSearch()} placeholder="Describe your partnership need here....." style={{flex:1,border:"1.5px solid #c8d8cc",borderRadius:9,padding:"11px 15px",fontSize:13,background:"#fff",color:"#1a3a2a",fontFamily:"Georgia,serif",fontWeight:600}} />
{/* ── RIGHT SIDEBAR ── */}
Partner Network
Results to Partner Enquiry
{COMPANIES.map(c=>{}}/>)}
)} {/* ══ PROFILES TAB ══ */} {tab==="profiles"&&(
Select Company
{COMPANIES.map(c=>{setSelCo(co);setProfTab("overview");}}/>)}
{selCo&&(
{/* Profile header */}
{selCo.logo}
{selCo.name}
{selCo.type}
📍 {selCo.location}
{/* Score ring with centred label */}
=90?"#4a9e6e":selCo.score>=80?"#c9a84c":"#c0392b"} ${selCo.score*3.6}deg,rgba(255,255,255,0.15) 0deg)`,display:"flex",alignItems:"center",justifyContent:"center"}}>
{selCo.score}
Partnership
Score
{selCo.capabilities.map(cap=>( {cap} ))}
{/* Profile sub-tabs */}
{PTABS.map(t=>( ))}
{/* Profile content */}
{profLoading&&!profVisible ?(
AI aggregating live intelligence...
):(
{profTab} Intelligence
AI Live Feed
{PROFILE_DATA[profKey]||"Loading..."}
✦ AI-aggregated intelligence from public sources. Member verification recommended before partnership decisions.
) }
{selCo.alerts>0&&(
⚠ Active Alert
AI has flagged a recent change in this company's profile. A regulatory authority inspection observation was recently published for the Palomonte site. Review recommended before advancing partnership discussions.
)}
)}
)}
); }